Bellevue Healthcare (LON:BBH) Shares Down 0.5% - Here's What Happened

Key Points

• Bellevue Healthcare shares fell 0.5% to GBX 124 ($1.66) on Tuesday, with trading volume declining by 59% compared to the average daily volume.
• The company reported a negative return on equity of 4.48% and a net margin of 169.10% in its last earnings results on August 7th.
• Bellevue Healthcare is an investment trust focused on global healthcare equities, aiming for a total dividend of 3.5 pence per ordinary share for the upcoming financial period.

Shares of Bellevue Healthcare (LON:BBH - Get Free Report) were down 0.5% on Tuesday . The stock traded as low as GBX 123.40 ($1.66) and last traded at GBX 124 ($1.66). Approximately 839,329 shares traded hands during trading, a decline of 59% from the average daily volume of 2,068,219 shares. The stock had previously closed at GBX 124.60 ($1.67).

Bellevue Healthcare Stock Performance

The firm's 50-day moving average price is GBX 116.57 and its two-hundred day moving average price is GBX 118.37. The stock has a market cap of £147.01 million and a price-to-earnings ratio of -472.92.

Bellevue Healthcare (LON:BBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported GBX 0.19 EPS for the quarter. Bellevue Healthcare had a net margin of 169.10% and a negative return on equity of 4.48%.

Bellevue Healthcare Company Profile

Bellevue Healthcare Trust plc is a high conviction, long-only investment trust invested in listed or quoted global healthcare equities. It is unconstrained and able to invest regardless of market cap, sub sector or region, and the portfolio is concentrated with a maximum of 35 holdings. The target total dividend in the first financial period is 3.5 pence per ordinary share (to be paid mostly out of capital) and in subsequent financial years will be set at 3.5 per cent.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.